Semax Reported Routes, Amounts, and Study Designs

Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.

This deep dive summarizes routes, reported amounts (when present), and study-design characteristics for the peptide Semax as described in the provided reviewed sources. The literature set emphasizes animal models of cerebral ischemia, spinal cord injury, and Alzheimer's disease, plus a single acute human functional MRI study; many protocol-level parameters (dose, systemic route, repeated dosing schedules) are not specified in the reviewed excerpts. [S2,S3,S5,S7,S8]

Routes reported in the reviewed literature

The reviewed excerpts describe Semax being administered (for example, S2 refers to an 'injection' in the human imaging study), but explicit systemic or local administration routes are not specified in the provided excerpts; for the animal studies the route of Semax delivery is not reported in the reviewed source. [S2,S3,S8] ^{[S2] [S3] [S8]}

Amounts and dosing details reported

Specific amounts (dose), concentration, and repeated-dosing schedules are not reported in the reviewed source excerpts for the human or animal studies; where timing or sampling points are provided, they are reported below but dose and route details are absent from the reviewed material. [S2,S3,S5,S8] ^{[S2] [S3] [S5] [S8]}

Study designs and models (human, animal, and cell)

The reviewed set includes: a human acute functional-connectivity study in healthy volunteers with pre- and post-injection resting-state fMRI (S2); multiple rodent ischemia studies using pMCAO or tMCAO with genome-wide RNA-Seq/timepoint comparisons (S5,S6,S8); a mouse spinal cord injury (SCI) impact model with behavioral and histological outcomes plus cell-model analyses (S3); and transgenic mouse models of Alzheimer's disease with behavioral and histological endpoints (S7). These studies span fMRI endpoints (human), transcriptomics and histology (rodent brain ischemia), behavioral and functional-recovery scores (SCI and Alzheimer’s models), and cell-based neuroinflammation experiments (reported in the SCI study). [S2,S3,S5,S6,S7,S8] ^{[S2] [S3] [S5] [S6] [S8] [S7]}

Human evidence (acute imaging study)

A functional-connectomic study enrolled 52 healthy participants and performed resting-state fMRI before and after Semax (and Selank or placebo) injections, with imaging repeated before, and at 5 and 20 minutes after injection; the excerpt does not specify the injection route or the administered amount. [S2] ^[S2]

Preclinical (animal and cell) evidence, timing, and mechanistic findings

Rodent ischemia studies include permanent middle cerebral artery occlusion (pMCAO) and transient MCAO (tMCAO) models. Genome-wide transcriptional analyses reported Semax-associated changes at acute timepoints (3 and 24 hours after pMCAO in S8) and at 4.5 and 24 hours after tMCAO in S5, with Semax reducing ischemia-related transcriptome distortions for many genes related to immune response, vascular processes, neurogenesis, angiogenesis, and signaling pathways. The reviewed excerpts do not report dosing or route details. [S8,S5,S6] ^{[S8] [S5] [S6]}

Other preclinical findings include a mouse spinal-cord-injury study (female C57BL/6 mice, T9–T10 impact) where Semax improved functional-recovery measures, inhibited lysosomal membrane permeabilization-related pyroptosis, decreased oxidative stress, and regulated USP18 with a proposed interaction at the μ-opioid receptor; details of dose and route are not reported in the reviewed excerpt. In a transgenic APPswe/PS1dE9 mouse Alzheimer’s model, Semax and a derivative improved cognitive-behavioral performance and reduced amyloid inclusions in cortex and hippocampus; protocol dosing details are not reported in the reviewed excerpt. [S3,S7] ^{[S3] [S7]}

Reported study-design details from cited sources

The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.

Limitations and research gaps

• The reviewed excerpts frequently omit critical protocol parameters (dose, route, frequency, and duration); where those parameters are absent they are explicitly recorded as 'not reported in the reviewed source' in protocol rows.
• Evidence is heavily weighted toward preclinical rodent models and in vitro analyses; only one acute human imaging study is present in the reviewed set, limiting translational certainty.
• Mechanistic links reported (e.g., μ-opioid receptor interaction, USP18/FTO deubiquitination, immune/vascular transcriptome modulation) are derived from single or preclinical reports in the provided excerpts and require broader confirmation.

Documentation checklist

• Evidence base is predominantly preclinical (rodent and cell models); human data in the reviewed set is limited to an acute imaging study.
• Most reviewed excerpts describe Semax administration but do not report explicit amounts, systemic routes, or repeated-dosing schedules.
• When study design timing is reported, timepoints are typically acute (minutes) in the human imaging study and hours to days in rodent ischemia models.
• Mechanistic signals reported include modulation of immune- and vascular-related gene expression in ischemia, regulation of ubiquitination pathways (USP18/FTO) and a proposed μ-opioid receptor interaction in spinal cord injury models.
• Protocol details (amount, route, frequency, duration) are often listed as 'not reported in the reviewed source' below when not explicitly given in the excerpts.

Related research supplies

• Laboratory sample labeling supplies (cryovial labels, barcodes)
• Cold-storage organization racks for vials and plates
• RNA sample handling consumables (RNase-free tubes, RNA stabilization reagents)
• Benchtop surface disinfectant compatible with laboratory equipment

Sources and references

1. [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
2. [S2] Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV. Functional Connectomic Approach to Studying Selank and Semax Effects.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020. PMID: 32342318. DOI: 10.1134/S001249662001007X
3. [S3] Liu R, Chen Y, Huang H, Li X, Lv J, Jiang L. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.. British journal of pharmacology. 2025. PMID: 40692165. DOI: 10.1111/bph.70122
4. [S4] Tarasov VV, Kudryashov NV, Chubarev VN, Kalinina TS, Barreto GE, Ashraf GM. Pharmacological Aspects of Neuro-Immune Interactions.. Current pharmaceutical design. 2018. PMID: 28875850. DOI: 10.2174/1381612823666170829135115
5. [S5] Filippenkov IB, Shpetko YY, Stavchansky VV, Denisova AE, Gubsky LV, Andreeva LA. ACTH-like Peptides Compensate Rat Brain Gene Expression Profile Disrupted by Ischemia a Day After Experimental Stroke.. Biomedicines. 2024. PMID: 39767736. DOI: 10.3390/biomedicines12122830
6. [S6] Filippenkov IB, Shpetko YY, Ales DA, Stavchansky VV, Denisova AE, Yuzhakov VV. Genes That Associated with Action of ACTH-like Peptides with Neuroprotective Potential in Rat Brain Regions with Different Degrees of Ischemic Damage.. International journal of molecular sciences. 2025. PMID: 40650034. DOI: 10.3390/ijms26136256
7. [S7] Radchenko AI, Kuzubova EV, Apostol AA, Mitkevich VA, Andreeva LA, Limborska SA. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.. Acta naturae. 2025. PMID: 41479572. DOI: 10.32607/actanaturae.27808
8. [S8] Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis.. BMC genomics. 2014. PMID: 24661604. DOI: 10.1186/1471-2164-15-228

Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.